{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T16:31:20.842698+00:00","company":{"ticker":"SRPT","cik":873303,"company_name":"Sarepta Therapeutics, Inc."},"pagination":{"limit":100,"returned":7,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"35b9c15265d0cc28d00e96ec29a69a84909170e2","cik":873303,"ticker":"SRPT","company_name":"Sarepta Therapeutics, Inc.","filed_at":"2026-05-06T23:59:59+00:00","payload":{"eps_text":"$2.88","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$331.0 million","period_text":"first quarter 2026","report_date":"2026-05-06","result_type":"reported_results","revenue_text":"$330.5 million"},"claim":"Sarepta Therapeutics, Inc. reported first quarter 2026 results: revenue $330.5 million, net income $331.0 million, EPS $2.88. Guidance reaffirmed.","evidence_excerpt":"Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments – Net product revenues for the first quarter 2026 totaled $330.5 million, consisting of $102.0 million of ELEVIDYS net product revenue and $228.6 million of PMO net product revenues – Achieved GAAP and non-GAAP operating income of $358.4 million and $397.7 million for the first quarter 2026, respectively","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-208966","anchor_url":"https://secwatch.observer/filing/0001193125-26-208966#claim-35b9c15265d0cc28d00e96ec29a69a84909170e2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/873303/000119312526208966/0001193125-26-208966-index.htm"},{"fact_type":"debt_financing","fact_key":"439382dbb2f6a5c5498f69360a86074a0d0a62d3","cik":873303,"ticker":"SRPT","company_name":"Sarepta Therapeutics, Inc.","filed_at":"2025-12-19T23:59:59+00:00","payload":{"counterparty":"certain holders (including Michael A. Chambers Living Trust)","effective_date":"2025-12-18","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"4.875%","item_codes_triggered":["2.03"],"maturity_text":"due 2030","principal_text":"approximately $291.4 million"},"claim":"Sarepta Therapeutics, Inc. incurred convertible notes of approximately $291.4 million with certain holders (including Michael A. Chambers Living Trust) at 4.875% maturing due 2030.","evidence_excerpt":"the holders party thereto agreed to exchange with the Company approximately $291.4 million in aggregate principal amount of Existing Convertible Notes held by them for consideration consisting of (i) approximately $291.4 million in aggregate principal amount of 4.875% Convertible Senior Notes due 2030 (the “New Convertible Notes”) and (ii) an aggregate of approximately $31.6 million in cash.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-326969","anchor_url":"https://secwatch.observer/filing/0001193125-25-326969#claim-439382dbb2f6a5c5498f69360a86074a0d0a62d3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/873303/000119312525326969/0001193125-25-326969-index.htm"},{"fact_type":"debt_financing","fact_key":"6688c6e36041d4f532bab75bbe7bcca8e208f25b","cik":873303,"ticker":"SRPT","company_name":"Sarepta Therapeutics, Inc.","filed_at":"2025-08-29T23:59:59+00:00","payload":{"counterparty":"U.S. Bank Trust Company, National Association","effective_date":"2025-08-28","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"4.875%","item_codes_triggered":["2.03"],"maturity_text":"September 1, 2030","principal_text":"$602.0 million in aggregate principal amount"},"claim":"Sarepta Therapeutics, Inc. incurred convertible notes of $602.0 million in aggregate principal amount with U.S. Bank Trust Company, National Association at 4.875% maturing September 1, 2030.","evidence_excerpt":"party thereto agreed to exchange with the Company $700.0 million in aggregate principal amount of Existing Convertible Notes held by them for consideration consisting of (i) $602.0 million in aggregate principal amount of 4.875% Convertible Senior Notes due 2030 (the “New Convertible Notes”), (ii) an aggregate of 5,851,693 shares of the Company’s common stock, par","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-192794","anchor_url":"https://secwatch.observer/filing/0001193125-25-192794#claim-6688c6e36041d4f532bab75bbe7bcca8e208f25b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/873303/000119312525192794/0001193125-25-192794-index.htm"},{"fact_type":"restructuring_charge","fact_key":"cf2668fb35c15d522cbb5c8ec68489d7c334013d","cik":873303,"ticker":"SRPT","company_name":"Sarepta Therapeutics, Inc.","filed_at":"2025-07-16T23:59:59+00:00","payload":{"affected_area":null,"charge_text":"between approximately $32 million and $37 million","effective_date":"2025-07-14","event_type":"restructuring","headcount_text":"approximately 36% of the Company's workforce","item_codes_triggered":["2.05"]},"claim":"Sarepta Therapeutics, Inc. announced a restructuring with charges of between approximately $32 million and $37 million (approximately 36% of the Company's workforce).","evidence_excerpt":"on July 14, 2025, the Board of Directors of the Company (the “Board”) approved a reduction in force, representing approximately 36% of the Company’s workforce. As a result of this reduction in force, the Company estimates that it will record a one-time charge in the third quarter of 2025 related to employee termination benefits, including severance, between approximately $32 million and $37 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-25-096257","anchor_url":"https://secwatch.observer/filing/0000950170-25-096257#claim-cf2668fb35c15d522cbb5c8ec68489d7c334013d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/873303/000095017025096257/0000950170-25-096257-index.htm"},{"fact_type":"executive_change","fact_key":"b0d04d7414","cik":873303,"ticker":"SRPT","company_name":"Sarepta Therapeutics, Inc.","filed_at":"2024-11-26T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-11-26","interim":false,"role":"Executive Vice President, General Counsel","role_category":"general_counsel","successor_name":null,"successor_named":false},"claim":"Cristin Rothfuss was appointed as Executive Vice President, General Counsel at Sarepta Therapeutics, Inc..","evidence_excerpt":"Cristin Rothfuss, the Company’s Senior Vice President, Deputy General Counsel, will succeed Mr. Brown as the Company’s Executive Vice President, General Counsel.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-265627","anchor_url":"https://secwatch.observer/filing/0001193125-24-265627#claim-b0d04d7414","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/873303/000119312524265627/0001193125-24-265627-index.htm"},{"fact_type":"executive_change","fact_key":"97947a5676","cik":873303,"ticker":"SRPT","company_name":"Sarepta Therapeutics, Inc.","filed_at":"2024-11-26T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-11-26","interim":false,"role":"Executive Vice President, Chief General Counsel","role_category":"general_counsel","successor_name":"Cristin Rothfuss","successor_named":true},"claim":"Ryan Brown resigned as Executive Vice President, Chief General Counsel at Sarepta Therapeutics, Inc..","evidence_excerpt":"Ryan Brown informed Sarepta of his resignation from his position as the Company’s Executive Vice President, Chief General Counsel, effective as of November 26, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-265627","anchor_url":"https://secwatch.observer/filing/0001193125-24-265627#claim-97947a5676","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/873303/000119312524265627/0001193125-24-265627-index.htm"},{"fact_type":"executive_change","fact_key":"53c179630f","cik":873303,"ticker":"SRPT","company_name":"Sarepta Therapeutics, Inc.","filed_at":"2024-09-16T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-09-12","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Deirdre Connelly was appointed as Director at Sarepta Therapeutics, Inc..","evidence_excerpt":"On September 12, 2024, the board of directors (the “ Board ”) of Sarepta Therapeutics, Inc. (the “ Company ”) appointed Deirdre Connelly as a director of the Company, effective immediately, to serve as a member of Class I until the 2026 annual meeting of stockholders.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000950170-24-106619","anchor_url":"https://secwatch.observer/filing/0000950170-24-106619#claim-53c179630f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/873303/000095017024106619/0000950170-24-106619-index.htm"}]}